Your shopping cart is currently empty

ZD 2486 is a glycoprotein IIb/IIIa (GP IIb/IIIa) antagonist. It inhibits platelet aggregation by blocking the binding of fibrinogen to the GP IIb/IIIa receptors on platelets. ZD 2486 is applicable in research concerning diseases linked to undesirable platelet aggregation, such as acute coronary syndromes, unstable angina, acute myocardial infarction, and complications from cardiovascular interventions.
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | ZD 2486 is a glycoprotein IIb/IIIa (GP IIb/IIIa) antagonist. It inhibits platelet aggregation by blocking the binding of fibrinogen to the GP IIb/IIIa receptors on platelets. ZD 2486 is applicable in research concerning diseases linked to undesirable platelet aggregation, such as acute coronary syndromes, unstable angina, acute myocardial infarction, and complications from cardiovascular interventions. |
| Molecular Weight | 355.44 |
| Formula | C20H25N3O3 |
| Cas No. | 185836-64-0 |
| Smiles | O(C[C@@H](CC(O)=O)C)C1=CC=C(N2CCN(CC2)C=3C=CN=CC3)C=C1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.